:/

Shuzo Urata1, Tomoko Tsuruta2, Manabu Igarashi3

  • 1Department of Medical and Applied Virology, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan; Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.

Virology
|May 20, 2025
PubMed
概括

抗寄生虫药物苏拉明通过抑制病毒的进入和复制,对抗竞技病毒感染具有前途. 这种双重作用机制表明,对淋巴细胞胆膜炎病毒 (LCMV) 产生抗药性的风险较低.